Haematology Trials - includes Bone Marrow Transplant, Myelodysplasic Syndrome and Other Haematology Trials
The following list provides a brief description of haematology trials that are recruiting participants in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
- Bone Marrow Transplant
- Myelodysplasic Syndrome
- Other Haematology Trials
- Haematology Trials including Leukaemia, Lymphoma, Myeloma
Bone Marrow Transplant
Reach 2
Registered Title | A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation |
Purpose | The purpose of the study is to assess the efficacy of Ruxolitinib when added to immunosuppression therapy in patients with Grade II-IV steroid refractory acute graft vs. host disease. |
Lay Summary | To evaluate the safety and efficacy of ruxolitinib compared to Best Available Therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation |
WA Trial Sites | ![]() Fiona Stanley Hospital Haematology |
Links | US National Library of Medicine |
Acknowledgements:US National Library of Medicine
Myelodysplasic Syndrome
CC-486-MDS-006 Myelodysplastic Disorders Study (Not Recruiting)
Registered Title |
A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine. |
Purpose |
Evaluate the safety and efficacy of CC-486 and Durvalumab in Subjects with Myelodysplastic Syndromes who failed to achieve an objective response post iHMA treatment. |
Lay Summary |
N/A |
WA Trial Sites |
RPH Haematology |
Links |
MDS-MSC01 Myelodysplastic Disorders Study
Registered Title |
Mesenchymal stromal cells as therapy for Myelodysplaisa of Low and Intermediate IPSS prognostic risk. |
Purpose |
N/A |
Lay Summary |
Myelodysplasia is a malignant disease of bone marrow failure. It occurs due to abnormal production of blood components (cells). It presents with low blood counts (anaemia, thrombocytopenia, neutropenia) and its complications include fatigue, bleeding, infections and transformation to acute myeloid leukaemia. Life expectancy is significantly reduced by this disease. Prognosis in MDS is classified from low to high risk based on the IPSS (WHO, 2001) which better predicts overall survival and progression to acute leukaemia. Low and intermediate-1 risk patients with MDS (considered for this study) would have median overall survival of 3.4-5.7 years. Standard care for patients with MDS is supportive (i.e. blood transfusions, treatment of infections). There are significant impacts to quality of life for this disorder due to frequent hospital presentations, transfusion, infections and a lack of treatment options. |
WA Trial Sites |
RPH Haematology |
Links |
N/A |
Other Haematology Trials
PCYC-1140-IM
Registered Title | Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE) |
Purpose | To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD. |
Lay Summary | N/A |
WA Trial Links | ![]() Fiona Stanley Hospital Haematology |
Links | US National Library of Medicine |
Acknowledgements: US National Library of Medicine
ALXN-1210-PNH-301 Paroxysmal Nocturnal Hemoglobinuria Study (Not Recruiting)
Registered Title |
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). |
Purpose |
The purpose of this study is to assess ALXN1210 compared to eculizumab in adult patients with PNH who have not previously used a complement inhibitor. |
Lay Summary |
N/A |
WA Trial Sites |
Perth Blood Institute |
Links |
Aplastic Anaemia Registry
Registered Title |
Aplastic Anaemia Registry (AA). |
Purpose |
The aims of the Aplastic Anaemia Registry are to: 1) Better define the incidence of AA in Australia; 2) Provide information on the range of therapeutic strategies being employed in the treatment of AA patients, including IST, HSCT and supportive care; 3) Explore factors influencing clinical outcomes; 4) Investigate the relationship of PNH clones to progress of disease and response to therapy; 5) Better define optimal management of AA patients Inform and inspire future hypothesis-driven research in this area. |
Lay Summary |
N/A |
WA Trial Sites |
Haematology Care Centre RPH Haematology Fiona Stanley Hospital Haematology |
Links |
N/A |
APMAT1 Microangiopathic Thrombocytopenia Study
Registered Title |
A Multi-centre, Observational Study by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network To Determine The Clinical Characteristics, Laboratory Features, Treatments, and Clinical Outcomes in Patients with Microangiopathic Thrombocytopenia. |
Purpose |
This is an observational study of patients who have previously been diagnosed and treated for Microangiopathic Thrombocytopenia (MAT). The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatments, and clinical outcome. |
Lay Summary |
N/A |
WA Trial Sites |
Perth Blood Institute |
Links |
C16011 - A study of MLN9708 in patients with Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Registered Title |
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients with Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis. |
Purpose |
The purpose of this study is to find out if MLN9708 plus dexamethasone improves against systemic light chain amyloidosis better than the physician's choice chemotherapy treatment. Physician's choice chemotherapy treatment is a treatment regimen that is commonly used to treat amyloidosis patients. The study will also determine if MLN9708 plus dexamethasone can change the chance that the amyloidosis will cause heart and/or kidneys to begin to work poorly needing care in the hospital or of dying. Another purpose of this study is to see how differences in DNA, RNA and proteins related to the disease may influence the way people respond to MLN9708. This information may be used by the Sponsor of this study, Millennium Pharmaceuticals, its agents and its affiliated companies for research related to analysis and development of MLN9708 and associated disease states, for example:
|
Lay Summary |
This is a phase 3, randomized, controlled, open-label, multicenter study of the oral formulation of dexamethasone plus MLN9708 compared with treatment chosen by the investigator from a prespecified list of regimens available in clinical practice. Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or lenalidomide) in patients with relapsed or refractory AL amyloidosis. Crossover to the investigational treatment arm is not permitted during participation in this study. |
WA Trial Sites |
Haematology Care Centre |
Links |
Acknowledgements: US National Library of Medicine
HERCULES Acquired Thrombotic Thrombocytopenic Purpura Study
Registered Title |
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura. |
Purpose |
The study is a phase III, double blind, placebo-controlled, randomized study to evaluate the efficacy and safety of caplacizumab treatment in more rapidly curtailing ongoing microvascular thrombosis when administered in addition to standard of care treatment in subjects with an acute episode of acquired TTP. |
Lay Summary |
N/A |
WA Trial Sites |
RPH Haematology |
Links |
MEPO Study
Registered Title |
Mepolizumab Compassionate Use Supply Program (SB240563.MHE104317). |
Purpose |
The purpose of this programme is to provide a treatment option to patients with life-threatening Hypereosinophilic Syndrome (HES) whose symptoms are not controlled with other therapies and to provide continued access to mepolizumab for subjects who received clinical benefit in Study MHE100901 following termination of the study. |
Lay Summary |
Eligible patients will receive a supply of Mepolizumab for monthly infusions with up to 10mg/kg (maximum dose 750mg or 10mg/kg if body weight less than 45kg) Mepolizumab IV for an initial three months of treatment. The duration and frequency of additional treatment with Mepolizumab will be determined based on the subject's response to the initial three months of treatment as demonstrated by significant lowering of eosinophil level and/or decreased signs and symptoms of HES. |
WA Trial Sites |
Haematology Care Centre |
Links |
Acknowledgements: US National Library of Medicine
MPN01 Registry
Registered Title |
Australasian Leukaemia and Lymphoma Group Myeloproliferative Neoplasms Registry. |
Purpose |
The aim of this registry is collect information on patients in Australia and New Zealand who have been diagnosed with a myeloproliferative neoplasm (polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic eosinophilic leukaemia) or a related disorder (hypereosinophilic syndrome, refractory anaemia with ringed sideroblasts associated with a marked thrombocytosis) and to understand the nature of the disease in the local area. |
Lay Summary |
The registry is an observational study and participating does not mandate the performance of investigations and does not recommend any treatment. The registry will collect information at the time the blood disorder was diagnosed which will include information about the haematological disease, the presence of comorbidities (other illnesses), family history of blood disorders, complications present in the disease and any therapies started. More information will be collected for the registry every 12 months on the progress of the disease, its therapy and any complications that may have developed for as long as the registry remains open. Patients will be offered the opportunity to complete a quality-of-life assessment (MPNSAF: myeloproliferative neoplasm symptom assessment form) within the first three months of diagnosis and on an annual basis. Patients will be asked to provide consent to obtain additional blood, bone marrow & saliva samples If they wish to take part in the optional scientific studies. |
WA Trial Sites |
Haematology Care Centre |
Links |
PNH Registry
Registered Title |
A global, observational, non-interventional study collecting effectiveness, safety and quality of life data on patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) Disease. |
Purpose |
The Registry will evaluate safety data specific to the use of Soliris,and will collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris and non-Soliris treated patients. The registry also aims to raise PNH awareness in the medical community and subject/potential subject population. |
Lay Summary |
The registry will enrol patients treated with Soliris for any reason, as well as patients with PNH. Clinical data will be collected from patients enrolled in this study. Participants will also be required to complete six monthly quality of life questionnaires. |
WA Trial Sites |
Haematology Care Centre, Fiona Stanley Hospital Haematology Perth Blood Institute |
Links |
Acknowledgements: US National Library of Medicine
TTP Registry
Registered Title |
Thrombotic Thrombocytopenic Purpura (TTP) Registry. |
Purpose |
The aims of the TTP Registry are to:
|
Lay Summary |
The TTP Registry will be a register of patients who develop TTP in any clinical setting. Clinical data collection will be undertaken by clinicians in specialist units at participating hospitals. Data management and analysis will be undertaken by the Department of Epidemiology and Preventive Medicine (DEPM), Monash University and interpreted with the input of Transfusion Medicine Specialists at ARCBS and specialist clinicians on the Registry Steering Committee. The Registry began collecting data in December 2008. Patients are identified either by the treating clinician, or by ARCBS clinicians as a result of referral for provision of blood components for therapy. Patient liaison and registration will take place in participating hospitals. Recruitment strategies take advantage of the fact that all patients will require blood component therapy provided by ARCBS, and patients are largely managed by a small group of specialised clinicians in a limited number of major centres with apheresis facilities. Registry staff will maintain close interaction with key individuals working in relevant hospital clinical care areas to ensure notification of all patients. |
WA Trial Sites |
Haematology Care Centre |
Links |
N/A |
[Return to List of Clinical Trials]